Latest Rituximab Stories
IMBRUVICA Combination Data in Chronic Lymphocytic Leukemia to be Featured in Official ASCO Press Program SUNNYVALE, Calif., May 13, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
WHIPPANY, N.J., April 14, 2015 /PRNewswire/ -- Bayer HealthCare today announced the expansion of its global clinical development program for the investigational oncology compound copanlisib (BAY
New report from Kantar Health shows opportunities for biosimilars are high in oncology, low in rheumatoid arthritis in China. Shanghai, China (PRWEB) December
- Anthera to receive up to $48,000,000 plus future product margin on commercial supply HAYWARD, Calif., Dec. 15, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
- Note: This press release corresponds to abstracts 4453 and 4471 SAN FRANCISCO, Dec.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
Health Canada approves GAZYVA((TM)) (obinutuzumab), a medicine that harnesses the body's immune system to kill cancer cells, for patients with chronic lymphocytic leukemia (or CLL)
Comprehensive market research report “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.